


## Supplemental material




Supplemental Figure S1. Achievement rates for EASI 75 (a), EASI 90 (b), EASI 100


(c), and absolute EASI  $\leq 2$  (d) in week 12 achievers or non-achievers during treatment

with upadacitinib 15 mg or 30 mg daily, excluding patients with a history of treatment

with upadacitinib 15 mg.



Supplemental Figure S2. Achievement rates for IGA 0/1 in week 12 achievers or non-achievers during treatment with upadacitinib 15 mg and 30 mg daily, excluding patients with a history of treatment with upadacitinib 15 mg.



Supplemental Figure S3. Achievement rates for PP-NRS 4 (a) or PP-NRS  $\leq 1$  (b) in week 12 achievers or non-achievers during treatment with upadacitinib (15 mg or 30 mg daily), excluding patients with a history of treatment with upadacitinib 15 mg.